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Penicillin resistance among Streptococcus pneumoniae is becoming a global problem. Different evolutionary phases in 
the development of resistance can be differentiated according to  the local distribution of bacterial strains with different 
levels of penicillin resistance: susceptible, early phase, low-level resistance phase, multipopulational phase, high-level 
resistance phase and very high-level resistance phase. These phases evolve in different periods (cryptic, penetration 
period, evolutionary period and stationary period) which describe the presumed natural history of the resistant 
organisms. The selective effect of the antibiotic usage depends on the amount and type of the drug, and also on the 
evolutionary period dominating the geographic area where the antibiotic is used. Macrolide resistance is also a growing 
problem, probably proportional t o  the amount of drug used. In the case of 0-lactams, ’more is different’ strategies may 
be useful t o  control clinically low-level resistant strains with aminopenicillins, and could slow the evolution to  higher 
rates of resistance in some areas; nevertheless, surveillance of the evolution of high-level resistance is mandatory. In 
Haemophilus influenzae, the proportion of P-lactamase-positive strains is also very high, frequently over 25% of cases; 
in all casesthe combination amoxycillin-clavulanate restores the susceptible phenotype. In this case, surveillance should 
be focused on the increase in non-P-lactamase-mediated penicillin resistance and fluoroquinolone resistance, or in  the 
potential evolution towards extended-spectrum 0-lactamases. 
During the last two decades, the leading pathogens 
involved in acute otitis media, Streptococcus pnetirnoniae 
and Haemophilus injuenzae, have evolved to reach un- 
expected levels of antibiotic resistance to the oral drugs 
traditionally used to control this clinical condition. 
Certainly, the increasing antibiotic resistance among 
otitis isolates reflects the general evolutionary trend 
of these pathogens. Any type of antibiotic treatment 
directed to control respiratory tract infections, or even 
focused on other infections, provokes a selective 
pressure on S. pneumoniae and H. injuenzae. As members 
of the normal nasopharyngeal microbiota, the dis- 
semination of strains among human populations is very 
effective, and therefore the spread of resistant organisms 
is assured, even without further antibiotic selection. 
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These phenomena have created the world crisis of 
antibiotic resistance. 
STREPTOCOCCUS PNEUMONIAE 
Penicillin-resistant pneumococci: a world crisis 
The estimated current prevalences (1993-1996) of 
penicillin resistance around the world are shown in 
Figure 1. About 200 local frequencies of penicillin 
resistance (MIC = X.1 mcg/mL) have been collected. 
Although a certain degree of heterogeneity in the 
clinical origin of the strains and sometimes in the 
quality of the data was unavoidable, the map expresses 
the geographic dimension of the problem of pneumo- 
coccal resistance to antibiotics, and suggests that we are 
approaching a real pandemic situation. The analysis of 
the available world data on the local frequencies of 
penicillin-resistant pneumococci provides several clues 
of epidemiologic interest that have been considered 
recently [l]. The fact that one group of geographic 
points has minimal prevalence of penicillin resistance 
(approximately less than 8%), a second group has a 
high prevalence (more than 20%), and the number of 
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Figure 1 A representation of the current prevalence rates of penicillin resistance (MIC =>0.1 mcg/mL) around the world. 
Black dots represent towns where penicillin-resistant pneuniococci have been detected. The sizes of the points represent the 
local percentage of resistance, from >=40%1 to 10%). 
locations with intermediate incidence rates is relatively 
low, suggests that intermediate prevalence rates tend to 
be relatively short-lived. These rates niay represent a 
rapid transitional phase from low prevalence to high 
prevalence rates [2,3]. Both of these features suggest the 
presence of a critical threshold in the percentage of 
antibiotic resistance, which can be estimated at about 
8%. Beyond this critical percentage, a rapid population 
penetration of resistant organisms is expected to 
occur. 
Evolutionary phases and periods in pneumococcal 
penicillin resistance 
Recent analysis of the data provided by the Alexander 
Project, a collaborative international surveillance study 
on respiratory pathogens [4], suggests that in the 
evolution of Streptococcus pueumoniae penicillin-resistant 
populations several evolutionary phases could be 
distinguished: (1) susceptible phase, where essentially a 
single susceptible population is detectable at  very low 
penicillin concentrations (0.008-0.03 mcg/mL); (2) 
early phase, where other populations began to appear, 
but presenting very small increases in MIC (0.06-0.12 
mcg/mL), this phase being probably reversible to the 
first; (3) low-level resistance phase, with an increase in the 
number of strains belonging to the 0.06-0.12 nicg/niL 
inhibited populations; moreover, some populations 
appear at  0.25-0.5 mcg/mL as well as very occasional 
strains at higher concentrations, 1-2 mcg/mL; (4) multi- 
populational phase, where the susceptible population 
slightly decreases, the low-level resistant population 
remains, and a clear increase in the populations 
inhibited by 1-2 mcg/mL is observed; (5) high-level 
resistance phase with a clear decrease in low-level 
resistant populations, and further increase in popu- 
lations inhibited by 1-2-4 mcg/mL. Eventually, a 
phase (6) very high-level resistancv phase, may occur, with 
a shift of the populations inhibited by 1-2 mcg/niL 
to 4 mcg/niL; in some countries strains with MIC 16 
mcg/mL have already appeared. 
These phases, reflecting the populational landscape 
of pneumococcal populations in different geographic 
areas, have recently been summarized in several 
evolutionary periods [ 11 considering the presumed 
natural history of the development of penicillin 
resistance. 
In a first cryptic period, in the absence of resistant 
organisms, the natural mutational events may produce 
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bacterial variants with decreased susceptibility to p- 
lactams. Nevertheless, in S. pneurnoniae most of these 
‘early’ mutants show an extremely low increase in MIC 
[5,6]. The genetic analysis of the modified PBP genes 
has revealed that the problem of p-lactam resistance 
in S. pneurnoniae was probably originated in other 
Streptococcus sp., such as S. rnitis, that transferred by 
transformation to pneumococci the gene(s) encoding 
modified (resistant) PBPs [6]. It can be suggested that 
the detection of an increase in the local prevalence of 
penicillin-resistance among viridans streptococci may 
serve as a warning signal of the next appearance of 
resistant pneumococci. But even if that was the 
case, the first rounds of transformation would yield 
S. pneurnoniae with very low MICs [5]. Additionally, 
these early resistant organisms may have had to pay a 
‘cost’ because of the altered functions of the remodeled 
resistant PBP(s), reducing their fitness in competition 
with the populations of wild pneumococci. Most of 
these relatively low-sized populations of ‘early’ resistant 
pneumococci may have been suppressed by the anti- 
biotic concentrations obtained in the patient. During 
the 1950s and 1960s many countries predominantly 
used penicillins by the intramuscular route (frequently 
in combination with streptomycin), and these types 
of practices (including other antibiotic combination 
therapies) may have contributed to the slow emergence 
of resistance. The much wider application of penicillins 
at the end of the 1960s, as a consequence of the 
development of oral aminopenicillins, and particularly 
the use of these agents at low or irregular dosages, has 
most probably influenced the enrichment of low-level 
resistant variant populations. 
The cryptic period is followed by a period of 
emergence of resistance. The enrichment of low- 
level resistant populations has immediate consequences. 
First, in these populations the efficiency of uptake by 
transformation of new genetic fragments involved in 
penicillin resistance appears to be greatly favored [5]. 
The resulting increase in MIC permits a more efficient 
selection by p-lactam agents. Second, the ‘cost’ of 
resistance, which presumably had limited the spread 
of resistant variants, begins to be compensated for at 
this stage by the appearance of new variants with 
genetic ‘compensatory’ alterations, leading to abnormal 
cell wall composition [7,8], and the eventual re- 
establishment of the fitness of the resistant organisms. 
These emerging resistant populations probably belong 
to a limited number of serogroups. It is known that, 
among the more frequent S. pneurnoniae serogroups, 
two sets can be recognized. Serogroups 1, 3, 4, 5, 7, 11, 
15 and 18 infrequently show penicillin resistance, while 
serogroups 6, 9, 14, 19 and 23 are much more 
frequently resistant [9]. That was already evident in 
the earlier resistant isolates [5], suggesting that this 
early evolution of penicillin resistance probably had 
historically occurred-and possibly through many 
different genetic events-in these serogroups. The 
reason for this may be their high prevalence in the 
normal nasopharyngeal flora of children, probably 
related to their poor immunogenicity, good mucosal 
adherence properties [9], and slow autolysis (Tomasz, 
personal communication). Good colonizers and lysis- 
defective strains may well have a better chance of 
taking up and incorporating DNA fragments encoding 
resistance determinants [lo]. O n  the other hand, and 
considering the high consumption of antibiotics in 
children, these serogroups have certainly been repeat- 
edly challenged by oral p-lactam agents. 
During the penetration period, two features are 
essential to explain the rapid dispersal of penicillin- 
resistant S. pneurnoniae populations among human 
communities. 
1. The spread of resistant organisms due to their 
spontaneous colonization ability. Remember that 
the pneumococcal serogroups with higher pre- 
valence of resistance may be among the best 
colonizers. This will increase the number of carriers, 
who will thus become new sources of colonizing 
organisms. In areas with a high frequency of 
‘colonizable humans’-read children-this spread 
will be very effective, particularly if some crowding 
conditions (as in day-care centers, camps or schools) 
are present [ 1 1-1 31. 
2. The effect of local antibiotic consumption. In this 
phase, a good correlation between the historical or 
year-by-year levels of p-lactam consumption and 
the annual growth rate in percentage of resistant 
strains has been observed in some developed 
countries [2,4,14]. Obviously the effect of the 
antibiotics is to reduce the total size of susceptible 
pneumococcal populations, and hence their pos- 
sibilities of colonizing new human hosts. The 
penicillin-resistant populations are expected to be 
proportionately increased in size, thus increasing 
their possibilities of colonization. The result is a very 
rapid change in the prevalence of resistance, due to 
the dispersion of a relatively low number of bacterial 
clones. The same phenomenon has been recently 
documented with regard to cephalosporin resistance 
[15]. O n  many occasions, an interplay between both 
factors is expected to occur: the combination of 
high antibiotic selective pressure and a high pro- 
portion of ‘colonizable’ hosts is very effective in 
selecting resistance. Rapid spread of resistance among 
child communities [ l l ]  has been detected in con- 
ditions of increased antibiotic consumption. 
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The next step is the geographic spread of resistance, 
with country-to-country clonal dispersion of resistant 
strains [ 16-18]. In summary, the penetration period 
niay be forniulated as an advancing-wave model, 
combining spatial diffusion with population growth. 
Both parameters will favor the next phase. 
For many countries, the future of p-lactani therapy 
of pneuniococcal otitis depends on the evolution from 
the former resistance situation. In this evolutionary 
period, and once a critical number of humans are 
colonized with low-level resistant S. pneumniae  strains, 
the possibility increases for each one of them to be 
confronted with new antibiotic challenges and with 
new potential donors of resistant p l y  genes. New 
rounds of transformation with other resistant strepto- 
cocci will increase its penicillin MIC [5], leading to 
a sequential acquisition of new ‘resistant’ alterations 
in the PBPs. Transforniants receiving the pbpla 
and pbp2x genes are typically low-level resistant strains, 
but the acquisition of pbp2b clearly produces a more 
resistant phenotype [ 151. Further rearrangements 
in pbp2b increase even niore the MIC [19-211, 
apparently until a limit of 8-1 6 mcg/mL. The selection 
of low-level variants will be favored by low-level 
antibiotic concentrations [22]. O n  the other hand, the 
evolutionary trend from low-level resistance (roughly 
0.06 to 0.25 mcg/mL) to higher resistance levels may 
occur without further increase of antibiotic use. 
Certainly, an acceleration of the process is expected 
under strong antibiotic selection, as the more resistant 
strains are also the more selectable by p-lactams. 
This evolution should progressively convert low-level 
resistant pneuniococcal populations into high-level 
resistant populations. The future dynamics of this 
process remain to be observed. Possibly, new waves of 
low-level resistant populations will reappear, leading to 
new secondary increases in high-level resistant strains. 
If the p-lactani therapeutic schedules are adapted to 
deal with the resistant strains (for instance increasing the 
dose), a further evolution of highly resistant strains 
towards even niore high-penicillin MICs cannot be 
ruled out. Nevertheless, a limit in the evolution may 
occur, because of the excessive cost in fitness of 
organisms harboring extensively remodeled resistant 
PBPs. 
Is there a natural end to this process? I n  some 
countries where a high prevalence of penicillin-resistant 
S. pneirmoiziae has been reached, this proportion 
apparently tends to stabilize during time, and this 
has been described as the sfationavy period. This may 
reflect a lack of new hosts to colonize for the resistant 
serogroups (habitat saturation). A relatively low pro- 
portion of children in the human community, or 
an increase in non-colonizable hosts, because of the 
development of group-specific local (herd) immunity, 
niay indeed slow or stabilize the quantitative progress 
of pneuniococcal resistance. Paradoxically, the develop- 
ment of penicillin resistance in the whole oropharyn- 
geal flora (as in viridans streptococci) may prevent 
the antibiotic-mediated ‘ecological vacuum’ which is 
expected to facilitate the colonization by resistant 
piieuniococci. A quite interesting possibility to explain 
natural liniitations in the spread of penicillin resistance 
is the potential interference with penicillin-susceptible 
S. pueumuiae  clones harboring resistance mechanisms 
to other antibiotics. For instance, macrolide- or 
quinolone-resistant serotypes may be efficiently selected 
by the increasing use of these antibiotics. If the involved 
serotypes do not correspond to the ‘penicillin-resistant’ 
serotypes, a ‘counterselection’ of penicillin resistance 
niay take place. An example of this phenomenon niay 
be Italy, with low rates of penicillin resistance and 
growing rates of niacrolide resistance. Obviously, in an 
environment where both p-lactams and macrolides are 
extensively used, the expected bacterial evolution will 
be directed to multiresistance. 
Evolutionary phases and antibiotic selection of penicillin 
resistance 
In the European Union [4], the lowest rates of p-lactani 
prescription occur in Germany and Italy, which also 
have very low rates of S.  pueunroniae resistance. At the 
other extreme, the highest rates of prescription occur 
in Spain and France, where penicillin resistance is very 
high. Nevertheless, the annual prescription rate in the 
UK approaches that of France and is consistently higher 
than that found in the USA. Nevertheless, penicillin 
resistance remains low in the UK, if compared with that 
found in the USA and particularly in France. These 
differences suggest that the selective effect of antibiotic 
usage on resistant S. yneumoniar may be dependent on 
the structure and density of the different populations 
present at  a given moment in a particular area. For 
instance, in the UK, as long as the current number o f  
penicillin-resistant pneumococci remains very low, the 
selective effect of antibiotics should also be low. 
Nevertheless, if a high consumption of antibiotics is 
occurring in this type of situation, the import of a 
resistant strain(s) could have deleterious consequences. 
During the low-level or multipopulational phases (see 
above), the possibility that the p-lactani antibiotics will 
contribute to the selection of already present low-level 
resistant bacterial populations is quite possible. In 
particular, the use of antibiotics with poor activity 
against these intermediate strains may result in an 
important selective pressure. In vitro experiments on 
selection support this hypothesis [22,23]. The role in 
this respect of most oral cephalosporins could be 
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considered. It is important to note that the amino- 
penicillins/cephalosporins ratio of usage (referring to 
prescriptions/l000 inhabitants) in France was 5.7 in 
1983, 4.5 in 1985, 3.1 in 1987, 2.3 in 1989 and only 
1.7 in 1992. The sharp relative increase in the use of 
cephalosporins may be related to the simultaneous 
increase in penicillin-resistant S. pneumoniae. In the 
UK, with a stably maintained very low rate ofpenicillin 
resistance, the ratio of prescriptions of aminopeni- 
cillins/cephalosporins has been maintained at over 4 
during the 1980-93 period. In the USA, on the other 
hand, where an increasing number of resistant S. 
pneumoniae isolates are detected, the aminopenicillins/ 
cephalosporins ratio has constantly been =<2 during 
the 1985-93 period (1.79 in 1989; 1.66 in 1991 and 
1.58 in 1993). I t  has been suggested 141 that the overuse 
of oral cephalosporins could be selecting penicillin 
resistance in S. pneumoniae. 
Resistance to macrolides 
The MIC distribution analysis of S. pneurnoniae strains 
suggests a trimodal pattern, with susceptible strains 
being inhibited by < I  mcg/mL; low-level resistant 
isolates having MICs 1-8 mcg/mL, and resistant 
strains having MICs =>16 mcg/mL. The importance 
of the ‘intermediate’ strains has been underestimated 
for several years, and they have even been considered as 
‘accidents’ of non-carefully controlled susceptibility 
testing procedures. Nevertheless, it can be suspected 
that many of these strains may harbor specific drug- 
efflux mechanisms of resistance; eventually they may 
contain MLS-type resistance of low inducibility. The 
high-level resistant strains probably harbor an evmAA4 
determinant responsible for high-level resistance. 
In the published data of the Alexander Project 
(1992-93) [4], high-level macrolides resistance in the 
European Union was found-nearly 10% on average. 
Erythromycin resistance is maintained at relatively low 
rates among penicillin-susceptible isolates (3-5%), but 
is much higher in penicillin-intermediate strains (about 
20%) and is particularly high among penicillin-resistant 
isolates (about 30% in 1993). In the USA, erythromycin 
resistance was less prevalent (less than 5%). The 
countries with the higher proportion of high-level 
macrolide resistance (France and Spain within the 
European Union) are those where the macrolides 
consumption is also higher; a critical threshold of about 
200 yearly prescriptions/ 1000 inhabitants has been 
suggested to trigger the dispersion of erythroniycin 
resistance. 
New antibiotic strategies: ’more is different‘? 
In the case of aminopenicillins, a ‘more is different’ 
strategy is being extensively applied to maintain 
p-lactam therapy in resistant S. pneumoniae isolates 
the attainable organic antibiotic levels are expected to 
inhibit the resistant organisms. From a theoretical point 
of view, and also from the results of in vitro modelling 
experiments [22], it is possible that the increase in the 
dosage may limit the evolution of low-level resistant 
mutants towards high-level resistance. The success of 
such a strategy should be inversely proportional to the 
distance in MIC of resistant mutants with respect to the 
susceptible population. Nevertheless, if the expected 
antibiotic levels do not surpass those of the resistant 
organisms, this group will be selected. At the level of 
the individual patient, high aminopenicillin (amoxy- 
cillin) dosages have been useful to treat infections due 
to penicillin-resistant strains. Even at the standard 
dosages, and excluding meningitis, some authors are 
unable to find significant differences in the outcome 
of their patients when treating with p-lactams pneu- 
monia or sepsis due to penicillin-susceptible and 
-resistant S. pneumoniae [24,25], and thus resistance 
was considered as having ‘little clinical significance’. 
Nevertheless, even in these studies, subgroups of 
patients infected with resistant bacteria tend to respond 
less well to therapy. The relationship between level of 
resistance and outcome is more patent in otitis, 
meningitis and experimental infections [26-281. In 
general, a patient with a resistant S. pneumoniae should 
be considered as having an increased risk of failure 
under conventional p-lactam therapy. 
HAEMOPHILUS IlVFLUElVZAE 
Beta-lactamase-producing Haemophilus intuenzne (BLP 
group) have amoxycillin MICs ranging from 4 to 32 
mcg/mL. Accordingly, with the data obtained during 
the first two years of the Alexander Project [4], these 
strains represent in the European Union (mean yearly 
rates) 15520% of the isolates, the figures being higher 
in the USA (20-30%). Despite apparent susceptibility 
to cefaclor in some cases, these BLP strains should 
be considered as non-treatable with first-generation 
cephalosporins. In the USA, many of them require 8 
mcg/niL of cefaclor to be inhibited, suggesting that 
they may be p-lactamase hyperproducer strains (for 
instance as a result of a gene-copy effect). Amoxycdin- 
resistant non-P-lactamase producers (l3LNAR group) 
are easily identified by cefaclor MICs ranging between 
32 and =>64 mcg/niL, and cefuroxime MICs of 8-16 
mcg/mL. The proportion of this type of strain ranges 
from 3% to 5% in the European Union, with some 
exceptions (about 10% in Spain), and is approximately 
3-8% in the USA. 
The possibility that the same evolutionary trends 
occurring in the TEM p-lactamase enzynies of Entero- 
B a q u e r o  e t  a l :  C u r r e n t  p a t t e r n s  a n d  e v o l u t i o n  o f  a n t i b i o t i c  r e s i s t a n c e  a m o n g  b a c t e r i a l  p a t h o g e n s  3S31 
bacteriaceae, leading to the extended-spectrum enzymes 
able to hydrolyze third-generation cephalosporins, may 
occur in H. infuenzae nierits close attention. It has been 
recently shown in Esclzevicliia coli (291 that some single 
mutations leading to specific aniino acid replacements 
in the TEM-1 p-lactamase may increase the MIC to 
cefotaxime in only a very modest way. In the 2718 
strains of H .  icfluenzae tested during 1992 and 1993 in 
the Alexander Project Study [4], the vast majority 
were inhibited by a concentration =<0.12 mcg/mL of 
ceftriaxone, but two strains required 0.5 or 1 nicg/mL 
for inhibition. These strains did not correspond to 
BLNAR isolates, which were consistently inhibited by 
0.12 mcg/niL. Fortunately, all P-lactamase-producing 
H .  infuenzae are isolates extremely susceptible to 
combined amoxycillin-clavulanic acid. The use of this 
combination niay slow the process of evolution if these 
enzymes are extended-spectrum enzymes. 
The susceptibility of H. inflcrenzae to macrolides 
remains a debatable question. The essentially mono- 
modal shape of the general ‘MIC/nuniber of strains’ 
distribution classically suggested that these strains have 
an intrinsic low susceptibility to niacrolides, but this 
cannot be considered as a true acquired resistance. 
Depending on the intrinsic activity of the different 
compounds, the MIC corresponding to the peak of the 
monomodal distribution varies slightly (4 mcg/niL for 
erythromycin and clarithromycin; 0.5 incg/niL for 
azithromycin) . Nevertheless, macrolides are drugs 
not to be recommended for H .  infuenzae. Fluoro- 
quiriolones are very active on H .  infuenzae (MIC 
lower than 0.06 iiicg/niL of ciprofloxacin for most 
isolates), although the use in otitis is severely hampered 
by the age of most of the infected patients. Recently, 
fluoroquiiiolone-resistant H .  inftwmze isolates have 
been detected in patients after prolonged fluoro- 
quinolone treatment [30]. 
profile to BRO-1, is produced in niuch lower 
quantities. In fact BRO-1 may have activity on cephalo- 
sporins, including ceftriaxone. Fortunately, anioxy- 
cillin-clavulanate conipletely restores susceptibility 
(MIC =<0.06 mcg/mL) in strains of the low-level 
penicillin-resistant population (BRO-2 phenotype), 
and significantly reduces the MIC of the high-level 
resistant population (BRO-I phenotype) to 0.12-0.5 
mcg/niL. In fact this combination is much more stable 
to BRO-1 than any other of the mentioned oral P- 
lactams. N o  strains were detected with resistance to the 
clavulanic acid inhibition. 
ANTIBIOTIC RESISTANCE IN ACUTE OTITIS MEDIA 
IN SPAIN 
Spain is one of the countries with a higher percentage 
of resistance among bacterial pathogens involved in 
acute otitis media. Surprisingly, very few studies are 
available concerning the rates of antibiotic resistance 
among isolates obtained in this clinical condition. The 
first prospective study on the bacteriology of acute 
otitis media, based on tympanocentesis performed on 
untreated patients, was recently published 1311. As 
expected, S. piieunzoniae and H .  in$uenzae were the 
leading pathogens, detected in 30% and 25% of cases 
respectively. Penicillin-resistant S. pneumoniae (MIC 
X . 1 2 5  mcg/niL) was found in 38.9% and high 
resistance (MIC 2 mcg/mL) in 16.7%. Beta-lactamase- 
positive H .  influenme was detected in 23.3% of 
the cases. Obviously, previous antibiotic therapy niay 
greatly increase the recovery of resistant isolates: in 
a new series, where treated patients were analyzed, 
the rate of penicillin resistance in S. pneumoniae was 
90.5% (42.1% of high-level resistance) and P-lactaniase 
production in H. injuenzae was 42.8% (F. del Castillo, 
personal communication). 
THE FUTURE 
MORAXELLA (BRANHAMELLA) CATARRHALIS 
The study of the penicillin distribution of MICs 
obtained during the first two years of the Alexander 
Project [4] revealed the existence of a p-lactamase- 
negative group of strains, which are inhibited by 0.06 
nicg/mL of penicillin G; a ‘low-level resistance’ group 
is formed by the strains inhibited by 0.25-2 nicg/mL 
and a ‘high-level resistance’ population is formed by the 
strains requiring 8 nicg/niL or more to be inhibited. 
Both resistant groups correspond to P-lactarnase- 
positive strains, probably BRO-I and BRO-2. The p- 
lactaniase-negative strains represented only 10-1 5% of 
the isolates in the European Union, and about 5% in 
the USA. The BRO-2 enzyme, with a similar substrate 
Antibiotic resistance in microorganisms involved in 
ear infections is becoming a global problem [32]. The 
quantitative evolution of this resistance may reach a 
saturation level in some countries with a very high rate 
of resistant strains; qualitatively, the resistant strains 
may evolve broadly to more effective mechanisms of 
resistance, particularly under the pressure of ‘more 
effective’ drugs of the same family introduced in the 
market. I n  countries with modest levels of antibiotic 
resistance, great attention should be paid to the abuse 
of drugs easily selecting ‘low-level resistant’ strains; 
in this respect, the study of the ratio of oral cephalo- 
sporin/aniinopenicillin use in the UK (with low ratio 
and low S. pneumoniae penicillin resistance) and the 
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USA (high ratio and high resistance) may be illustrative. 
Obviously, a similar selective effect of ‘low-level 
resistant’ strains may be caused by underdosage habits. 
It is extremely important to understand that 
antimicrobial resistance could be perhaps limited by a 
rational adaptation of the use of antibiotics only at  the 
very early stages. Later restrictions could be slightly 
effective, or would take a very long time to influence 
the resistance patterns. In fact, microbes could find 
‘ecological advantages’ in the possession of some 
resistant plasmids, transposons or mechanisms, inde- 
pendently of the presence or absence of antibiotics 
in the environment. Because of this, initiatives of 
surveillance of resistance around the world may be 
essential in the future to control the environmental 
health inipact of antibiotic$. 
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